D3 Bio focuses on discovering, developing, and registering innovative medicines that address key driver mutations and immune pathways in cancer. Its lead asset is elisrasib (D3S-001), a KRAS G12C inhibitor being advanced toward global Phase III pivotal trials as both a monotherapy and in combination regimens. The company’s broader pipeline spans targeted and immuno-oncology programs built on proprietary clinical insights and biomarker strategies, all of which it owns global rights to. The recent $108 million Series B financing underscores investor confidence in the firm’s scientific approach and global development capabilities. Proceeds will fund late-stage clinical development of elisrasib across the United States, China, and the European Union and support continued pipeline expansion. While specific revenue or patient enrollment figures were not disclosed, the successful raise highlights the company’s solid financial footing for its near-term clinical milestones.

Total raised

$370M

Funding rounds

3

Latest round

Series B

Latest activity

Dec 2025